-20℃ 3 years powder
-80℃ 2 years in solvent
SR0987 is a RORγt agonist,
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | 77.00 | |
10 mg | In stock | 131.00 | |
25 mg | In stock | 266.00 | |
50 mg | In stock | 446.00 | |
100 mg | In stock | 797.00 | |
1 mL * 10 mM (in DMSO) | In stock | 84.00 |
Description | SR0987 is a RORγt agonist, |
Targets&IC50 | RORγt :ic50 800 nM (EC50), |
In vitro | SR0987 treatment results in a statistically significant reduction of the surface expression of PD-1 whereas desmostrol treatment shows no effect. Treatment with SR0987 and or desmosterol results in a trend towards increased IL17 production.SR0987 clearly shows a concentration dependent induction of reporter gene expression with an EC50 of ~800nM. |
Molecular Weight | 397.7 |
Formula | C16H10ClF6NO2 |
CAS No. | 303126-97-8 |
-20℃ 3 years powder
-80℃ 2 years in solvent
DMSO: 10 mM
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.